pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,502 catalysts · 4,728 grant · 3,076 device 510k · 3,045 8k filing · 2,774 approval · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 16 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 8 catalysts2026-11-03: 17 catalysts2026-11-04: 22 catalysts2026-11-05: 36 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: grant×type: approval×from 2025-05-02×clear all
type
  • grant4,728
  • device 510k3,076
  • 8k filing3,045
  • approval2,774
  • device pma2,000
  • device recall2,000
device adverse event
1,000
  • recall751
  • earnings579
  • phase 2 completion172
  • therapy area

    no tagged catalysts yet

    Week of Apr 28, 2025

    1
    ›May 2, 2025approval466d agoTICAGRELOR — FDA approvalTICAGRELOR

    Sponsor: ALEMBIC. Form: TABLET. Route: ORAL

    full page →TICAGRELOR →fda approvals ↗

    Week of May 5, 2025

    6
    ›May 5, 2025approval463d agoTICAGRELOR — FDA approvalInvaGen Pharmaceuticals Inc

    Sponsor: INVAGEN PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›May 5, 2025approval463d agoFENSOLVI KIT (LEUPROLIDE ACETATE) — FDA approvalLEUPROLIDE ACETATE

    Sponsor: TOLMAR. Form: POWDER. Route: SUBCUTANEOUS

    full page →LEUPROLIDE ACETATE →fda approvals ↗
    ›May 6, 2025approval462d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: MACLEODS PHARMS LTD. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›May 7, 2025approval461d agoSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalrisankizumab

    Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INTRAVENOUS

    full page →risankizumab →fda approvals ↗
    ›May 7, 2025approval461d agoSKYRIZI (RISANKIZUMAB-RZAA) — FDA approvalrisankizumab

    Sponsor: ABBVIE INC. Form: INJECTABLE. Route: INJECTION

    full page →risankizumab →fda approvals ↗
    ›May 9, 2025approval459d agoBUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (ASPIRIN) — FDA approvalNovitium Pharma LLC

    Sponsor: LGM PHARMA. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗

    Week of May 12, 2025

    6
    ›May 12, 2025approval456d agoINREBIC (FEDRATINIB HYDROCHLORIDE) — FDA approvalfedratinib

    Sponsor: BRISTOL-MYERS. Form: CAPSULE. Route: ORAL

    full page →fedratinib →fda approvals ↗
    ›May 12, 2025approval

    Week of May 19, 2025

    25
    ›May 19, 2025approval449d agoSUBOXONE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalBUPRENORPHINE HYDROCHLORIDE

    Sponsor: INDIVIOR. Form: FILM. Route: BUCCAL, SUBLINGUAL

    full page →BUPRENORPHINE HYDROCHLORIDE →fda approvals ↗
    ›May 19, 2025approval

    Week of May 26, 2025

    12
    ›May 28, 2025approval440d agoTRULICITY (DULAGLUTIDE) — FDA approvaldulaglutide

    Sponsor: ELI LILLY AND CO. Form: INJECTABLE. Route: INJECTION

    full page →dulaglutide →fda approvals ↗
    ›May 28, 2025approval
    ← prev
    page 1 of 151
    next →
    456d ago
    TYENNE (TOCILIZUMAB-AAZG) — FDA approvalTYENNE

    Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: INTRAVENOUS

    full page →TYENNE →fda approvals ↗
    ›May 14, 2025approval454d agoKADCYLA (ADO-TRASTUZUMAB EMTANSINE) — FDA approvaltrastuzumab emtansine

    Sponsor: GENENTECH. Form: VIAL. Route: SINGLE-USE

    full page →trastuzumab emtansine →fda approvals ↗
    ›May 14, 2025approval454d agoCAPRELSA (VANDETANIB) — FDA approvalvandetanib

    Sponsor: GENZYME CORP. Form: TABLET. Route: ORAL

    full page →vandetanib →fda approvals ↗
    ›May 15, 2025approval453d agoSPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: SPRAY. Route: NASAL

    full page →fda approvals ↗
    ›May 15, 2025approval453d agoZYNYZ (RETIFANLIMAB-DLWR) — FDA approvalretifanlimab

    Sponsor: INCYTE CORP. Form: INJECTABLE. Route: INTRAVENOUS

    full page →retifanlimab →fda approvals ↗
    449d ago
    ZUBSOLV (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalEdenbridge Pharmaceuticals LLC

    Sponsor: EDENBRIDGE PHARMS. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›May 20, 2025approval448d agoAMJEVITA (ADALIMUMAB-ATTO) — FDA approvalAMJEVITA

    Sponsor: AMGEN INC. Form: INJECTABLE. Route: INJECTION

    full page →AMJEVITA →fda approvals ↗
    ›May 20, 2025approval448d agoCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalCYLTEZO

    Sponsor: BOEHRINGER INGELHEIM. Form: INJECTABLE. Route: INJECTION

    full page →CYLTEZO →fda approvals ↗
    ›May 20, 2025approval448d agoHYRIMOZ (ADALIMUMAB-ADAZ) — FDA approvalHYRIMOZ

    Sponsor: SANDOZ INC. Form: INJECTABLE. Route: INJECTION

    full page →HYRIMOZ →fda approvals ↗
    ›May 21, 2025approval447d agoHADLIMA (ADALIMUMAB-BWWD) — FDA approvalHADLIMA

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

    full page →HADLIMA →fda approvals ↗
    ›May 21, 2025approval447d agoHADLIMA (ADALIMUMAB-BWWD) — FDA approvalHADLIMA

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

    full page →HADLIMA →fda approvals ↗
    ›May 21, 2025approval447d agoYUFLYMA (ADALIMUMAB-AATY) — FDA approvalYUFLYMA

    Sponsor: CELLTRION. Form: INJECTABLE. Route: INJECTION

    full page →YUFLYMA →fda approvals ↗
    ›May 21, 2025approval447d agoYUFLYMA (ADALIMUMAB-AATY) — FDA approvalYUFLYMA

    Sponsor: CELLTRION. Form: INJECTABLE. Route: INJECTION

    full page →YUFLYMA →fda approvals ↗
    ›May 22, 2025approval446d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›May 22, 2025approval446d agoKALYDECO (IVACAFTOR) — FDA approvalVertex, Inc.

    Sponsor: VERTEX PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›May 22, 2025approval446d agoKALYDECO (IVACAFTOR) — FDA approvalivacaftor

    Sponsor: VERTEX PHARMS INC. Form: GRANULE. Route: ORAL

    full page →ivacaftor →fda approvals ↗
    ›May 22, 2025approval446d agoISOTRETINOIN — FDA approvalZydus Therapeutics Inc

    Sponsor: ZYDUS PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›May 22, 2025approval446d agoTECHNESCAN PYP KIT (TECHNETIUM TC-99M PYROPHOSPHATE KIT) — FDA approval

    Sponsor: CURIUM. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›May 22, 2025approval446d agoTECHNESCAN HDP (TECHNETIUM TC-99M OXIDRONATE KIT) — FDA approval

    Sponsor: CURIUM. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›May 22, 2025approval446d agoLUPRON DEPOT-PED KIT (LEUPROLIDE ACETATE) — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: ABBVIE ENDOCRINE INC. Form: POWDER. Route: INTRAMUSCULAR

    full page →fda approvals ↗
    ›May 22, 2025approval446d agoEBGLYSS (LEBRIKIZUMAB-LBKZ) — FDA approvallebrikizumab

    Sponsor: ELI LILLY AND CO. Form: INJECTABLE. Route: INJECTION

    full page →lebrikizumab →fda approvals ↗
    ›May 23, 2025approval445d agoOPDIVO (NIVOLUMAB) — FDA approvalnivolumab

    Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION

    full page →nivolumab →fda approvals ↗
    ›May 23, 2025approval445d agoBUPROPION HYDROCHLORIDE — FDA approvalBUPROPION HYDROCHLORIDE

    Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →BUPROPION HYDROCHLORIDE →fda approvals ↗
    ›May 23, 2025approval445d agoBUPROPION HYDROCHLORIDE — FDA approvalBUPROPION HYDROCHLORIDE

    Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →BUPROPION HYDROCHLORIDE →fda approvals ↗
    ›May 23, 2025approval445d agoBUPROPION HYDROCHLORIDE — FDA approvalBUPROPION HYDROCHLORIDE

    Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →BUPROPION HYDROCHLORIDE →fda approvals ↗
    ›May 23, 2025approval445d agoBUPROPION HYDROCHLORIDE — FDA approvalBUPROPION HYDROCHLORIDE

    Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →BUPROPION HYDROCHLORIDE →fda approvals ↗
    ›May 23, 2025approval445d agoWAKIX (PITOLISANT HYDROCHLORIDE) — FDA approvalpitolisant hydrochloride

    Sponsor: HARMONY. Form: TABLET. Route: ORAL

    full page →pitolisant hydrochloride →fda approvals ↗
    ›May 23, 2025approval445d agoBOSUTINIB MONOHYDRATE — FDA approvalBOSUTINIB MONOHYDRATE

    Sponsor: ALEMBIC. Form: TABLET. Route: ORAL

    full page →BOSUTINIB MONOHYDRATE →fda approvals ↗
    ›May 23, 2025approval445d agoOPDIVO QVANTIG (NIVOLUMAB) — FDA approval(hyaluronidase (recombinant, human) + nivolumab)

    Sponsor: BRISTOL-MYERS SQUIBB. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →(hyaluronidase (recombinant, human) + nivolumab) →fda approvals ↗
    440d ago
    SOLIQUA 100/33 (INSULIN GLARGINE) — FDA approvalToujeo LA

    Sponsor: SANOFI-AVENTIS US. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →Toujeo LA →fda approvals ↗
    ›May 28, 2025approval440d agoADLYXIN (LIXISENATIDE) — FDA approvalADLYXIN

    Sponsor: SANOFI-AVENTIS US. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →ADLYXIN →fda approvals ↗
    ›May 28, 2025approval440d agoSAXENDA (LIRAGLUTIDE) — FDA approvalNovo Nordisk Inc

    Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›May 28, 2025approval440d agoMOUNJARO (TIRZEPATIDE) — FDA approvalZEPBOUND

    Sponsor: ELI LILLY AND CO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →ZEPBOUND →fda approvals ↗
    ›May 28, 2025approval440d agoSPEVIGO (SPESOLIMAB-SBZO) — FDA approvalspesolimab

    Sponsor: BOEHRINGER INGELHEIM PHARMACEUTICALS INC. Form: INJECTABLE. Route: INTRAVENOUS

    full page →spesolimab →fda approvals ↗
    ›May 28, 2025approval440d agoSPEVIGO (SPESOLIMAB-SBZO) — FDA approvalspesolimab

    Sponsor: BOEHRINGER INGELHEIM PHARMACEUTICALS INC. Form: INJECTABLE. Route: INTRAVENOUS

    full page →spesolimab →fda approvals ↗
    ›May 28, 2025approval440d agoXULTOPHY 100/3.6 (INSULIN DEGLUDEC) — FDA approvalNovo Nordisk Inc

    Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›May 28, 2025approval440d agoVICTOZA (LIRAGLUTIDE) — FDA approvalSaxenda

    Sponsor: NOVO NORDISK INC. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →Saxenda →fda approvals ↗
    ›May 29, 2025approval439d agoFOCINVEZ (FOSAPREPITANT DIMEGLUMINE) — FDA approvalAthenex Inc (Inactive)

    Sponsor: STERISCIENCE. Form: SOLUTION. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›May 29, 2025approval439d agoMETHOTREXATE — FDA approvalMaxtrex

    Sponsor: ACCORD HLTHCARE. Form: SOLUTION. Route: INTRAVENOUS

    full page →Maxtrex →fda approvals ↗
    ›May 30, 2025approval438d agoACETAZOLAMIDE — FDA approvalACETAZOLAMIDE

    Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL

    full page →ACETAZOLAMIDE →fda approvals ↗
    $LLY1231.94+3.90%
    $INDV38.47-0.90%
    $BMY64.84+0.19%
    $ABBV247.97+0.78%
    $ABBV247.97+0.78%
    $VERX12.13+1.63%
    $VERX12.13+1.63%
    $INCY121.55+0.82%
    $AMGN417.20+1.52%
    $AMRX17.88-1.43%
    $LLY1231.94+3.90%
    $BMY64.84+0.19%
    $BMY64.84+0.19%
    $HRMY39.00+1.54%
    $LLY1231.94+3.90%
    $NVO47.73+0.99%